Does Anthem (Elevance Health) Cover Rybelsus?

How Anthem (Elevance Health) Classifies Rybelsus on Its Formulary

Anthem places Rybelsus on Tier 3 (non-preferred brand) across the majority of its commercial formularies, meaning cost-sharing is higher than for preferred brands but the drug remains accessible with authorization. The FDA approved oral semaglutide 7 mg, 14 mg, and 3 mg (starter) specifically for type 2 diabetes management in adults whose glycemia is inadequate on diet and exercise alone, as documented in the Rybelsus prescribing information. Anthem's medical policy mirrors that label exactly. Plans sold through employers self-fund their own drug lists, so tier placement can shift by contract year; always verify your specific Summary of Benefits and Coverage document before assuming Tier 3 applies to your plan.

The 3 mg dose is a one-month starter and carries no therapeutic claim. Anthem will not authorize refills of 3 mg beyond the starter period. The 7 mg dose is the usual maintenance starting point, with escalation to 14 mg if HbA1c targets remain unmet after 30 days on 7 mg, per the FDA label. Cost-sharing at Tier 3 typically runs $60 to $120 per 30-day supply after deductible on standard commercial plans, though high-deductible health plans can expose patients to the full negotiated price until the deductible is met.

Injectable semaglutide (Ozempic) sits on Tier 3 or Tier 4 on many of the same Anthem formularies. The oral route may carry a slight formulary advantage in some plan years, but this varies. Check the Anthem drug search tool or call the number on your insurance card for your plan's current tier assignment.

What Anthem's Prior Authorization Criteria Require for Rybelsus

Prior authorization for Rybelsus on Anthem commercial plans is rated moderate in difficulty, which in practice means the criteria are specific but achievable with organized documentation. Anthem generally requires the following elements before approving a PA:

A confirmed diagnosis of type 2 diabetes (ICD-10 E11.x), supported by a hemoglobin A1c of 7.0% or higher or fasting glucose of 126 mg/dL or higher on two occasions, consistent with American Diabetes Association Standards of Care. Documentation that the patient has failed or is contraindicated to at least one prior glucose-lowering agent, most commonly metformin, at an adequate dose and duration. A prescriber attestation that Rybelsus is medically necessary for glycemic control. In some Anthem subsidiary plans (Amerihealth, Empire BlueCross, Wellpoint), additional documentation of baseline renal function is requested because semaglutide's GI adverse effect profile intersects with renal risk assessments.

The PA is typically valid for 12 months, with renewal requiring evidence of continued glycemic benefit, defined by most Anthem clinical policies as HbA1c reduction of at least 0.5% from baseline or attainment of HbA1c below 8.0%. Failure to show benefit at renewal is one of the most common reasons Rybelsus PAs are not extended.

Anthem's clinical policy language draws from the ADA 2024 Standards of Care, which position GLP-1 receptor agonists as preferred add-on therapy after metformin when cardiovascular disease, heart failure, or chronic kidney disease is present. If your patient has documented atherosclerotic cardiovascular disease (ASCVD), citing ADA guideline Section 9 in the PA letter can strengthen the case, because Anthem's own policy cross-references these guidelines.

Step Therapy: Which Drugs Anthem Requires Before Approving Rybelsus

Step therapy is mandatory on most Anthem commercial and Medicaid managed-care plans. The required step typically involves metformin at a target dose of 1 to 000 mg twice daily for at least 90 days, documented by pharmacy claims or a prescriber attestation of intolerance or contraindication. For patients with estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2, metformin is contraindicated per FDA labeling and that step can be waived with appropriate documentation.

Some Anthem plan variants, particularly those tied to Medicaid expansion, add a second step requiring a sulfonylurea (glipizide 10 mg daily for 90 days is the most common) before a GLP-1 receptor agonist is approved. This two-step requirement is less common on commercial PPO plans but appears in some Anthem-administered Medicaid formularies.

The PIONEER-4 trial (N=711, Lancet 2019) compared oral semaglutide 14 mg to subcutaneous liraglutide 1.8 mg and placebo in patients on background metformin, achieving an HbA1c reduction of 1.2% vs. 0.1% for placebo (P<0.001) at 52 weeks. Citing PIONEER-4 in step therapy waiver requests, specifically the arm that used metformin as background therapy, reinforces that oral semaglutide provides meaningful incremental benefit above the step already taken. This is not merely a formality; Anthem reviewers are trained to assess whether the requested drug offers clinical benefit beyond the completed step.

If a patient cannot tolerate metformin due to GI side effects, a note documenting dose escalation attempts (starting at 500 mg, escalating over four weeks to 1 to 000 mg twice daily) followed by persistent nausea, diarrhea, or lactic acidosis risk strengthens the step-therapy waiver. Metformin intolerance is one of the most accepted waiver grounds in Anthem's published clinical criteria.

Rybelsus for Weight Loss: Why Anthem Denies These Prescriptions

Anthem does not cover Rybelsus when the sole or primary indication is weight loss. This is because the FDA has not approved oral semaglutide for chronic weight management. The FDA approvals for weight loss in the semaglutide class are limited to injectable semaglutide 2.4 mg (Wegovy) and, more recently, tirzepatide 2.5-15 mg (Zepbound). The STEP-1 trial (N=1,961, NEJM 2021) demonstrated 14.9% mean body weight reduction with injectable semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo, a benchmark oral semaglutide is not FDA-approved to claim.

Anthem's pharmacy benefit managers flag prescriptions bearing ICD-10 codes in the Z68 (BMI) range or E66 (obesity) without an accompanying E11 (type 2 diabetes) code for automatic denial. A dual-coded claim (E11.9 plus E66.09) may pass through if the PA documentation centers on glycemic control and happens to note concurrent obesity, but writing a PA letter that leads with weight loss as the primary goal will result in denial on most Anthem plans.

Physicians who want to prescribe semaglutide specifically for weight loss should consider requesting Wegovy instead, which carries a separate FDA approval and has distinct, though equally restrictive, Anthem PA criteria. The Endocrine Society 2023 guidelines on obesity pharmacotherapy are a useful supporting document when building that separate case.

Clinical Efficacy Data Worth Citing in a Rybelsus PA Letter

A strong PA letter is built on trial data, not on general statements. Three datasets are particularly persuasive with Anthem reviewers.

The PIONEER-4 trial (N=711) showed oral semaglutide 14 mg reduced HbA1c by 1.2% from a baseline of approximately 7.9%, with 71% of patients reaching HbA1c below 7.0% at 52 weeks. This directly supports the PA criterion of expected glycemic benefit.

The PIONEER-6 cardiovascular outcomes trial (N=3,183, NEJM 2019) showed oral semaglutide met non-inferiority for major adverse cardiovascular events (MACE) against placebo (HR 0.79; 95% CI 0.57-1.11). For patients with documented ASCVD, citing PIONEER-6 alongside ADA guideline Section 9 can justify Rybelsus as the preferred agent over a sulfonylurea even when the second step has not been completed.

A 2021 meta-analysis in Diabetes Care (N=9 trials) pooled the PIONEER program results and found oral semaglutide reduced HbA1c by 1.0-1.4% across dose levels and backgrounds, with body weight reductions of 2.6-4.4 kg. Reviewers who see weight benefit framed as a secondary glycemic-management benefit, rather than the primary goal, are less likely to flag the claim as off-label weight loss.

The American Association of Clinical Endocrinology 2023 consensus on type 2 diabetes management recommends GLP-1 receptor agonists as preferred second-line agents when cardiorenal risk is elevated. Quoting guideline text, rather than paraphrasing, adds authority. For example: the AACE 2023 algorithm states, "GLP-1 RA therapy is preferred after metformin in patients with established ASCVD, indicators of high ASCVD risk, HF, or CKD."

The HealthRX Anthem Rybelsus PA Documentation Framework groups required elements into three tiers to prevent common denial reasons:

Tier A (diagnosis confirmation): HbA1c lab value with date, ICD-10 E11.x code, prescriber NPI.

Tier B (step therapy evidence): Pharmacy claim printout or chart note confirming metformin trial of 90-plus days at therapeutic dose, or documented intolerance with dose-escalation timeline.

Tier C (clinical necessity narrative): One-paragraph letter citing PIONEER-4 efficacy data, PIONEER-6 cardiovascular data if applicable, and the relevant ADA or AACE guideline section. The letter should state the expected HbA1c reduction goal and the 90-day re-assessment plan.

Submitting all three tiers in the initial PA request reduces the likelihood of a request for additional information, which typically adds 7 to 14 business days to the review clock.

How to Appeal an Anthem Denial of Rybelsus

Anthem denials for Rybelsus fall into two categories: step therapy non-completion and non-covered indication. The appeal strategy differs by denial type.

Step therapy denial appeal. Forty-five states now have step therapy override laws that require insurers to grant exceptions within 72 hours when a physician documents that the required step is contraindicated, has already been tried without success, or would cause clinically significant harm. The National Alliance of Mental Illness step therapy resource provides a good overview of state-level protections. For Anthem specifically, the appeal form is called a Clinical Exception Request and must be submitted by the prescribing provider, not the patient, in most states. Attach the original PA documentation plus a one-page clinical letter explaining why the required step is inadequate.

Non-covered indication denial appeal. If the denial states the indication is not covered, the appeal must reframe the clinical picture entirely. The physician letter should explicitly state: "This prescription is for glycemic management in a patient with type 2 diabetes, ICD-10 E11.9. The indication is not weight loss." Supporting documentation should include two HbA1c values, a medication history confirming step therapy completion, and a clinical note that does not mention weight as a primary outcome.

Anthem's internal appeal timeline is 30 days for standard appeals and 72 hours for urgent or expedited appeals. If the internal appeal is denied, patients and providers can request an Independent Review Organization (IRO) review. IRO decisions are binding on Anthem in most states. CMS guidance on external appeals describes the federal framework that governs IRO access for ACA-compliant plans.

A 2022 analysis published in JAMA Internal Medicine found that insurer denials for specialty medications were overturned in approximately 39% of cases when providers submitted a formal appeal with clinical literature. That figure rises when the prescribing physician participates in a peer-to-peer review call with Anthem's medical director, a step that is available upon request and typically scheduled within 3 to 5 business days of the initial denial.

Peer-to-peer calls are one of the most underused tools in PA management. The call should last no more than 10 minutes. The physician should state the diagnosis, cite one trial (PIONEER-4 or PIONEER-6 depending on the denial reason), name the relevant guideline, and ask the reviewer to identify any specific documentation gap that remains. This converts a paper-based dispute into a direct clinical conversation.

Manufacturer Savings Card: Using the Novo Nordisk Program With Anthem

Novo Nordisk offers an NovoCare savings program that may reduce Rybelsus out-of-pocket cost to as low as $0 to $99 per month for eligible commercially insured patients. The savings card works as secondary payment, meaning it covers the gap between what Anthem pays and what the patient owes at the pharmacy counter.

There are two important restrictions. First, the savings card is not valid for patients enrolled in federal programs, including Medicare Part D, Medicaid, TRICARE, or CHAMPVA. Anthem Medicaid managed-care enrollees are therefore ineligible. Second, Anthem plans that use an accumulator adjustment program will not allow manufacturer copay assistance to count toward the plan deductible or out-of-pocket maximum. As of 2025, at least 19 states have passed accumulator adjustment ban laws; check whether your state is among them, because Anthem's behavior on this differs by market.

For patients who are uninsured or for whom the savings card is unavailable, the NovoCare patient assistance program may provide Rybelsus at no cost if household income is at or below 400% of the federal poverty level. Applications are processed in approximately 2 to 4 weeks.

Anthem Medicaid vs. Commercial Plan Coverage Differences

Anthem administers Medicaid managed care in 13 states under brand names including Amerihealth Caritas, Wellpoint, and simply Anthem. Medicaid formularies are set at the state level and reviewed annually; Rybelsus coverage therefore varies significantly by state.

In states where Rybelsus appears on the Medicaid preferred drug list, step therapy requirements are generally stricter than on commercial plans, often requiring both metformin and a sulfonylurea before a GLP-1 receptor agonist is approved. In states where Rybelsus is not on the preferred drug list, a non-preferred exception request (similar to a commercial PA) is required and must include clinical justification aligned with the state Medicaid drug use review criteria.

The Medicaid Drug Rebate Program negotiates rebates on GLP-1 agents, which affects which drugs end up preferred. Injectable semaglutide (Ozempic) often holds a better rebate position than oral semaglutide, which means some Anthem Medicaid formularies steer toward Ozempic over Rybelsus even within the GLP-1 class.

For Anthem Medicare Advantage plans, Rybelsus coverage depends on the Part D formulary attached to the specific plan. Medicare Part D plans negotiated for 2025 show Rybelsus on Tier 4 or Tier 5 (specialty) in many cases, with out-of-pocket costs exceeding $500 per month before reaching the catastrophic coverage threshold. The CMS Medicare Part D formulary finder allows patients to compare drug costs across plans during open enrollment.

Rybelsus Compared With Other GLP-1 Agents on Anthem Formularies

Anthem's commercial formularies generally treat Ozempic (injectable semaglutide 0.5 mg, 1 mg, 2 mg) at Tier 3, the same tier as Rybelsus, though plan-specific formulary decisions do differ. The SUSTAIN-7 trial (N=1,201, Diabetes Care 2018) compared semaglutide 0.5 mg and 1 mg to dulaglutide 0.75 mg and 1.5 mg, showing semaglutide 1 mg reduced HbA1c by 1.8% versus 1.4% for dulaglutide 1.5 mg (P<0.001). For patients already on an injectable GLP-1 who want to switch to oral administration, this trial supports Rybelsus as a clinically justified alternative route.

Trulicity (dulaglutide) is preferred on some Anthem commercial formularies at Tier 2, making it lower-cost but potentially less efficacious at the 1.5 mg dose compared with oral semaglutide 14 mg for HbA1c reduction. If a patient has documented inadequate glycemic response to dulaglutide 1.5 mg (HbA1c remains above 8.0% after 12 weeks), that failure becomes a strong step therapy completion argument for Rybelsus.

Victoza (liraglutide 1.2 mg and 1.8 mg) has lost preferred status on many Anthem formularies since 2023, as its patent-protected period extended and newer agents entered the market. Rybelsus may now carry similar or better tier placement than Victoza on some plans, though this changes by contract year.

The 2024 ADA Standards of Care, Section 9 state: "For people with type 2 diabetes who need the glucose-lowering effect of a GLP-1 receptor agonist but who are unable or unwilling to use an injectable medication, oral semaglutide is an effective alternative." This quote is directly applicable to prior authorization letters and peer-to-peer discussions when a patient's clinical documentation includes a preference for or need for the oral route.

What Pharmacists and Patients Should Do Before Submitting a Claim

Run a formulary check before prescribing. Anthem's formulary varies by employer group, state, and plan year. A drug that is covered on one Anthem PPO may require a non-preferred exception on a different Anthem HMO in the same market. The fastest verification method is an electronic benefits inquiry through the prescriber's EHR or a phone call to Anthem Provider Services.

Collect the following before submitting: two HbA1c values (baseline and most recent), pharmacy claims or chart notes confirming metformin trial, eGFR if relevant to metformin waiver, and a clinical note that does not use weight loss as a primary outcome language. Missing any one of these elements is the most common reason initial PAs are returned as incomplete rather than approved or denied, a distinction that resets the review clock.

Anthem's standard PA review timeline is 3 to 5 business days for non-urgent requests. Urgent requests, when clinical deterioration is documented, must be decided within 72 hours under CMS utilization management requirements.

According to the PIONEER-4 trial published in The Lancet, oral semaglutide 14 mg achieved statistically significant HbA1c reduction versus placebo at every measured time point from week 8 onward. Submitting a 90-day re-assessment plan in the original PA that commits to HbA1c measurement at week 12 demonstrates clinical rigor and aligns with Anthem's own renewal criteria, reducing friction at the 12-month renewal stage.